Gilead Sciences Veklury® (Remdesivir) was Approved by the US FDA
The U.S. FDA approved Gilead Sciences (GILD) antiviral drug Veklury® (remdesivir) for COVID-19 infected patients who require hospitalization. Veklury halts the SARS-CoV-2 replication that causes COVID-19.
Veklury is the first and only approved COVID-19 treatment (not vaccine) in the U.S.. The news announced that the drug is widely available in hospitals across the country. The product is approved for adults and pediatric patients (12 years of age and older and weighing at least 40 kg (88 lb)) with COVID-19 requiring hospitalization. The product should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care.
It is important to read all the additional Important Safety Information for Veklury®.